ONENESS BIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159 TWD | +3.92% |
|
+6.71% | -18.25% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 109,494 | 95,221 | 88,028 | 72,117 | - |
| Enterprise Value (EV) 1 | 109,494 | 89,566 | 88,028 | 67,003 | 72,117 |
| P/E ratio | -271 x | 270 x | -66.8 x | -883 x | -81.1 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 89.4 x | 1,213 x | 53.6 x | 233 x |
| EV / Revenue | - | 84.1 x | 1,213 x | 49.8 x | 233 x |
| EV / EBITDA | - | 354 x | -139 x | 153 x | - |
| EV / FCF | - | -92.5 x | - | -213 x | - |
| FCF Yield | - | -1.08% | - | -0.47% | - |
| Price to Book | - | 6.55 x | - | 4.62 x | - |
| Nbr of stocks (in thousands) | 433,310 | 441,294 | 452,586 | 453,563 | - |
| Reference price 2 | 252.7 | 215.8 | 194.5 | 159.0 | 159.0 |
| Announcement Date | 3/15/22 | 3/7/23 | 3/11/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,066 | 72.56 | 1,345 | 309 |
| EBITDA 1 | - | 253.2 | -634.9 | 437 | - |
| EBIT 1 | - | -241.4 | -1,070 | -198.5 | -895 |
| Operating Margin | - | -22.66% | -1,473.89% | -14.76% | -289.64% |
| Earnings before Tax (EBT) 1 | - | 451.6 | -1,308 | -88 | -900 |
| Net income 1 | -403.3 | 360 | -1,313 | -82 | -890 |
| Net margin | - | 33.78% | -1,809.28% | -6.1% | -288.03% |
| EPS 2 | -0.9317 | 0.7998 | -2.910 | -0.1800 | -1.960 |
| Free Cash Flow 1 | - | -968.3 | - | -315 | - |
| FCF margin | - | -90.88% | - | -23.42% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 3/15/22 | 3/7/23 | 3/11/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.85 | 14.78 | 22.19 | 19.89 | 19.03 | 11.45 | 25 | 382.5 | 80 | 857.5 | 34 |
| EBITDA 1 | - | -176 | -139.3 | -168.6 | - | -167.9 | -131 | -52 | -66 | 685 | - |
| EBIT 1 | - | -291.1 | -250.5 | -279.5 | - | -270.5 | -264.5 | -6 | -231.5 | 303 | -269 |
| Operating Margin | - | -1,969.87% | -1,128.86% | -1,404.95% | - | -2,361.3% | -1,058% | -1.57% | -289.38% | 35.34% | -791.18% |
| Earnings before Tax (EBT) 1 | - | -649.8 | -268.9 | -326 | - | -488.7 | -145.5 | -33 | -197 | 287.5 | -228 |
| Net income 1 | - | -642.7 | -264.7 | -335.2 | -226.6 | -486.3 | -145.5 | -28 | -196 | 287.5 | -225 |
| Net margin | - | -4,349.57% | -1,192.96% | -1,685.25% | -1,190.93% | -4,245.8% | -582% | -7.32% | -245% | 33.53% | -661.76% |
| EPS 2 | - | -1.459 | -0.5977 | -0.7400 | - | -1.070 | -0.3200 | -0.0600 | -0.4300 | 0.6350 | -0.5000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/28/22 | 3/7/23 | 5/15/23 | 8/11/23 | 11/13/23 | 3/11/24 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 5,655 | - | 5,114 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -968 | - | -315 | - |
| ROE (net income / shareholders' equity) | - | 2.51% | - | -0.59% | -6.81% |
| ROA (Net income/ Total Assets) | - | 2.3% | - | -0.57% | -6.47% |
| Assets 1 | - | 15,656 | - | 14,513 | 13,756 |
| Book Value Per Share 2 | - | 32.90 | - | 34.40 | - |
| Cash Flow per Share 2 | - | -1.970 | - | 0.3400 | - |
| Capex 1 | - | 87.3 | - | 83 | 61 |
| Capex / Sales | - | 8.2% | - | 6.17% | 19.74% |
| Announcement Date | 3/15/22 | 3/7/23 | 3/11/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
159
TWD
Average target price
262
TWD
Spread / Average Target
+64.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.25% | 2.21B | |
| +26.47% | 664B | |
| +26.74% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.43% | 234B | |
| +4.71% | 199B | |
| -9.53% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- 4743 Stock
- Financials Oneness Biotech Co., Ltd.
